Conatus制药

CNAT NASDAQ
0.3300
+0.0071
+2.20%
已收盘, 16:00 07/18 EDT
开盘
0.3276
昨收
0.3229
最高
0.3399
最低
0.3120
成交量
33.95万
成交均量(3M)
93.48万
52周最高
6.74
52周最低
0.2500
换手率
1.02%
市值
1,094.45万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Conatus制药 CNAT股票价格,Conatus制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
展开 >

最近浏览

名称
价格
涨跌幅